Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 18/20 | 0.85 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 1/20 | 0.45 |
| ▸ | ROS1 | P08922 | 1/20 | 0.45 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TYK2 | P29597 | 1/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.45 |
| ▸ | SIK1 | P57059 | 1/20 | 0.45 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 0.45 |
| ▸ | SIK3 | Q9Y2K2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL16446162 | 0.99 | TNK2 (0.84) | TNK2JAK2JAK1JAK3CHEK1 | |
| SCHEMBL16453409 | 0.96 | TNK2 (0.85) | TNK2JAK2JAK1JAK3CHEK1 | |
| Hydrochloric Acid SCHEMBL16446360 | 0.95 | TNK2 (0.84) | TNK2JAK2JAK1JAK3SIK1 | |
| SCHEMBL16453381 | 0.94 | TNK2 (0.81) | TNK2JAK2JAK1JAK3CHEK1 | |
| Hydrochloric Acid SCHEMBL16445850 | 0.93 | TNK2 (0.80) | TNK2JAK2JAK1JAK3CHEK1 | |
| SCHEMBL16447853 | 0.92 | TNK2 (1.00) | TNK2JAK2JAK1JAK3CHEK1 | |
| SCHEMBL20233956 | 0.88 | TNK2 (0.85) | TNK2JAK2JAK1JAK3CHEK1 | |
| SCHEMBL16447728 | 0.88 | TNK2 (0.84) | TNK2JAK2JAK1JAK3CHEK1 | |
| SCHEMBL16447895 | 0.86 | TNK2 (1.00) | TNK2JAK2CHEK1ABL1LCK | |
| SCHEMBL16445171 | 0.86 | TNK2 (1.00) | TNK2JAK2JAK1JAK3CHEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. | 2018-06-07 | — | — | US | disclosed |
| US-9850216-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2017-12-26 | — | — | US | disclosed |
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| WO-2015021149-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160176826-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885JAK2 597/4885JAK1 604/4885 |
| US-10017478-B2 | Inhibitors of ACK1/TNK2 tyrosine kinase | TNK1, TNNI3K, TNK2 | TNK2 3/4885JAK2 597/4885JAK1 604/4885 |
| US-20180155297-A1 | INHIBITORS OF ACK1/TNK2 TYROSINE KINASE | TNK1, TNNI3K, TNK2 | TNK2 3/4885JAK2 597/4885JAK1 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.